Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients (ONTRANS)
Unknown authors
Published in New England Journal of Medicine
Key Findings
Oral nicotinamide 500 mg twice daily did not lower the number of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients.
Conclusions
The DNA-repair benefit seen in immunocompetent patients did not extend to transplant recipients.
Supplements Studied
Oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients.
Oral nicotinamide 500 mg twice daily did not lower the number of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients.
Outcomes Measured
Oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.